Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | WRN | Q14191 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7249667 | 0.82 | SMN1; SMN2 (0.36) | ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL29048961 | 0.82 | SMN1; SMN2 (0.36) | ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL1928703 | 0.82 | SMN1; SMN2 (0.36) | ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL12505873 | 0.80 | MAPT (0.32) | MAPT | |
| SCHEMBL25475485 | 0.79 | MGAM (0.37) | NAAAALDH1A1MGAMGAASI | |
| SCHEMBL8706762 | 0.77 | TSHR (0.42) | NAAAALDH1A1MGAMGAASI | |
| SCHEMBL386957 | 0.77 | NAAA (0.39) | NAAAALDH1A1MGAMGAASI | |
| SCHEMBL16640289 | 0.77 | NAAA (0.31) | NAAA | |
| SCHEMBL7243118 | 0.76 | NAAA (0.32) | NAAAALDH1A1MGAMGAASI | |
| SCHEMBL195331 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115518156-B | Nanocomposite capable of releasing near-infrared thermic agent in response manner, preparation method and application | 西安交通大学医学院第二附属医院 | 2023-10-10 | — | — | CN | claimed |
| CN-109293926-B | Protease responsive linear-dendritic block copolymer and preparation method and application thereof | 云南师范大学 | 2021-04-23 | — | — | CN | claimed |
| CN-110628035-A | Enzyme and pH dual-responsive copolymer and preparation method and application thereof | 云南师范大学 | 2019-12-31 | — | — | CN | claimed |
| CN-1223583-C | Peroxyester preparation method | ATOFINA (FR) | 2005-10-19 | — | — | CN | claimed |
| CN-1491210-A | Process for preparing peroxyesters | ���з��ɹ�˾ | 2004-04-21 | — | — | CN | claimed |
| CN-117642410-A | Ester derivatives of N4-hydroxycytidine and uses thereof | 苏州春海生物医药有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-115518156-B | Nanocomposite capable of releasing near-infrared thermic agent in response manner, preparation method and application | 西安交通大学医学院第二附属医院 | 2023-10-10 | — | — | CN | disclosed |
| CN-116583530-A | N 4 Ester derivatives of hydroxycytidine and their use | 苏州春海生物医药有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-115518156-A | Nano compound for responsively releasing near-infrared photothermal agent, preparation method and application | 西安交通大学医学院第二附属医院 | 2022-12-27 | — | — | CN | disclosed |
| WO-2022262845-A1 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | SUZHOU SPRING-SEA BIO-PHARMACEUTICALS CO., LTD. (CN) | 2022-12-22 | — | — | WO | disclosed |
| CN-113474008-A | NRTI therapy | 利物浦大学 | 2021-10-01 | — | — | CN | disclosed |
| CN-109293926-B | Protease responsive linear-dendritic block copolymer and preparation method and application thereof | 云南师范大学 | 2021-04-23 | — | — | CN | disclosed |
| EP-1809280-A2 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060100161-A1 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | ARRAY BIOPHARMA INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006044825-A2 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| CN-1223583-C | Peroxyester preparation method | ATOFINA (FR) | 2005-10-19 | — | — | CN | disclosed |
| CN-1491210-A | Process for preparing peroxyesters | ���з��ɹ�˾ | 2004-04-21 | — | — | CN | disclosed |
| US-6632958-B1 | An alkene (1) is added to cyclopentenone (2) under the action of an alkyl lithium and an organic copper reagent to form an adduct, said adduct is reacted with e.g. a carboxylic anhydride (4) to obtain a prostaglandin derivative, which is | MITSUBISHI PHARMA CORPORATION (JP) | 2003-10-14 | — | — | US | disclosed |
| EP-1085012-A1 | PROCESS FOR PRODUCING PURIFIED PROSTAGLANDIN DERIVATIVE | Asahi Glass Co., Ltd. (JP) | 2001-03-21 | — | — | EP | disclosed |
| EP-0447553-B1 | BLEACHING COMPOSITION | KAO CORP (JP) | 1996-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100161-A1 | Antiproliferative agents; anticancer agents; autoimmune disease; antiarthritic agents; graft versus host disease; inflammatory bowel disorders | KIF5B, KIF2C, KIFC1 | NAAA 3664/4885ALDH1A1 1990/4885MGAM 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.